Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL) 25 x 5 mL Single Dose Vials, For Intravenous or Intramuscular Use, Preservative Free, Rx Only, Manufactured by: West-Ward Pharmaceuticals, Eatontown, NJ 07724, NDC 0641-6028-25.
Class I - DangerousWhat Should You Do?
- Check if you have this product: Lot #: 113312, Exp 11/2015; 014315 Exp 01/2016
- Do not eat it: Even if it looks and smells fine, do not consume this product.
- Throw it away or return it: You can return the product to the store for a full refund.
- Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
- Report problems: Report any issues to the FDA's Safety Reporting Portal.
⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.
Recall Details
- Company:
- West-Ward Pharmaceutical Corporation
- Reason for Recall:
- Failed Impurities/Degradation Specifications; 12 month stability testing.
- Classification:
- Class I - Dangerous
Dangerous or defective products that predictably could cause serious health problems or death.
- Status:
- terminated
Product Information
Full Description:
Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL) 25 x 5 mL Single Dose Vials, For Intravenous or Intramuscular Use, Preservative Free, Rx Only, Manufactured by: West-Ward Pharmaceuticals, Eatontown, NJ 07724, NDC 0641-6028-25.
Product Codes/Lot Numbers:
Lot #: 113312, Exp 11/2015; 014315 Exp 01/2016
Official Source
Always verify recall information with the official FDA source:
View on FDA.govFDA Recall Number: D-0420-2015
Related Recalls
PredniSONE Tablets USP, 1 mg, 100-count bottles, Rx only, Distr. by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-4741-25.
West-Ward Pharmaceutical
Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.
Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).
Subpotency: Out of Specification (OOS) result at the 36 month routine stability time point.